Wednesday, Dec 18, 2024
Serina Therapeutics (NYSE: SER)
Following up on some massive winners lately, I’ve found another fresh idea that I think has huge potential right now.
Go to your favorite platform and pull up Serina Therapeutics (SER) right now.
First of all, look at the powerful technical chart setup.Last time we saw “GO” signals from the AI-powered algo, it led to a 30% rally shortly after…
The scanner right now is showing fresh “GO” signals that just fired off.
This is a PERFECT TIME to get SER on your radar and start watching it immediately.
👉 SER is TODAY’S #1 ALERT 👈
As you do your homework on SER this morning, check out TipRanks.
Their technical analysis engine shows a perfect “STRONG BUY” right now on SER…
Serina Therapeutics (SER), a clinical-stage biotechnology company, is advancing innovative therapies for neurodegenerative diseases, notably Parkinson’s disease.
Here are some of the key points I think are important to consider…
Proprietary POZ Platform™ Technology 🎯
Serina’s POZ Platform™ is engineered to enhance drug delivery by offering greater control over drug loading and release rates. This technology addresses limitations found in other biocompatible polymers, such as polyethylene glycol (PEG), by minimizing immunogenicity and improving safety profiles.
Lead Candidate: SER-252 for Advanced Parkinson’s Disease 🧬
SER-252 (POZ-apomorphine) is Serina’s leading therapeutic candidate, designed to provide continuous dopaminergic stimulation (CDS) in patients with advanced Parkinson’s disease. Preclinical studies suggest that SER-252 can deliver CDS without causing skin reactions, potentially reducing motor complications associated with levodopa treatment.
Strategic Partnerships and Collaborations 🤝
- Enable Injections: Serina has partnered with Enable Injections to develop and commercialize SER-252 using Enable’s enFuse® wearable drug delivery platform. This collaboration aims to offer patients a convenient, less invasive treatment option.
Enable Injections - Pfizer: In November 2023, Serina entered into a non-exclusive license agreement with Pfizer, granting access to its POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations, underscoring the platform’s versatility and industry recognition.
GlobeNewswire
Recent Financial Milestone 🏆
In December 2024, Serina secured a $10 million equity financing from strategic shareholder JuvVentures (UK) Limited. This funding is intended to advance SER-252 into a Phase 1 clinical trial for advanced Parkinson’s disease patients by the second half of 2025.
Diverse Pipeline and Future Prospects 💊
Beyond SER-252, Serina is exploring the application of its POZ Platform™ across various therapeutic areas, including RNA-based therapeutics and antibody-drug conjugates (ADCs), indicating a broad potential to address multiple medical needs.
These strategic initiatives and technological advancements position Serina Therapeutics as a promising entity in the biotechnology sector, with significant potential to impact the treatment landscape for neurodegenerative diseases and beyond.
Put SER at the top of your watchlist right away!
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Legends Media for advertising Serina Therapeutics for a one day marketing program on December 18, 2024. This was paid by someone else not connected to Serina Therapeutics. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Serina Therapeutics might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.